Anuli C Uzozie1,2, Enes K Ergin1,2, Nina Rolf2,3, Janice Tsui1,2, Amanda Lorentzian2,3, Samuel S H Weng1, Lorenz Nierves1,2, Theodore G Smith1,2, C James Lim2,3, Christopher A Maxwell2,3, Gregor S D Reid2,3, Philipp F Lange4,5,6. 1. Department of Pathology, University of British Columbia, Vancouver, BC, Canada. 2. Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada. 3. Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. 4. Department of Pathology, University of British Columbia, Vancouver, BC, Canada. philipp.lange@ubc.ca. 5. Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada. philipp.lange@ubc.ca. 6. Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada. philipp.lange@ubc.ca.
Abstract
BACKGROUND: Murine xenografts of pediatric leukemia accurately recapitulate genomic aberrations. How this translates to the functional capacity of cells remains unclear. Here, we studied global protein abundance, phosphorylation, and protein maturation by proteolytic processing in 11 pediatric B- and T- cell ALL patients and 19 corresponding xenografts. METHODS: Xenograft models were generated for each pediatric patient leukemia. Mass spectrometry-based methods were used to investigate global protein abundance, protein phosphorylation, and limited proteolysis in paired patient and xenografted pediatric acute B- and T- cell lymphocytic leukemia, as well as in pediatric leukemia cell lines. Targeted next-generation sequencing was utilized to examine genetic abnormalities in patients and in corresponding xenografts. Bioinformatic and statistical analysis were performed to identify functional mechanisms associated with proteins and protein post-translational modifications. RESULTS: Overall, we found xenograft proteomes to be most equivalent with their patient of origin. Protein level differences that stratified disease subtypes at diagnostic and relapse stages were largely recapitulated in xenografts. As expected, PDXs lacked multiple human leukocyte antigens and complement proteins. We found increased expression of cell cycle proteins indicating a high proliferative capacity of xenografted cells. Structural genomic changes and mutations were reflected at the protein level in patients. In contrast, the post-translational modification landscape was shaped by leukemia type and host and only to a limited degree by the patient of origin. Of 201 known pediatric oncogenic drivers and drug-targetable proteins, the KMT2 protein family showed consistently high variability between patient and corresponding xenografts. Comprehensive N terminomics revealed deregulated proteolytic processing in leukemic cells, in particular from caspase-driven cleavages found in patient cells. CONCLUSION: Genomic and host factors shape protein and post-translational modification landscapes differently. This study highlights select areas of diverging biology while confirming murine patient-derived xenografts as a generally accurate model system.
BACKGROUND:Murine xenografts of pediatric leukemia accurately recapitulate genomic aberrations. How this translates to the functional capacity of cells remains unclear. Here, we studied global protein abundance, phosphorylation, and protein maturation by proteolytic processing in 11 pediatric B- and T- cell ALL patients and 19 corresponding xenografts. METHODS: Xenograft models were generated for each pediatric patientleukemia. Mass spectrometry-based methods were used to investigate global protein abundance, protein phosphorylation, and limited proteolysis in paired patient and xenografted pediatric acute B- and T- cell lymphocytic leukemia, as well as in pediatric leukemia cell lines. Targeted next-generation sequencing was utilized to examine genetic abnormalities in patients and in corresponding xenografts. Bioinformatic and statistical analysis were performed to identify functional mechanisms associated with proteins and protein post-translational modifications. RESULTS: Overall, we found xenograft proteomes to be most equivalent with their patient of origin. Protein level differences that stratified disease subtypes at diagnostic and relapse stages were largely recapitulated in xenografts. As expected, PDXs lacked multiple human leukocyte antigens and complement proteins. We found increased expression of cell cycle proteins indicating a high proliferative capacity of xenografted cells. Structural genomic changes and mutations were reflected at the protein level in patients. In contrast, the post-translational modification landscape was shaped by leukemia type and host and only to a limited degree by the patient of origin. Of 201 known pediatric oncogenic drivers and drug-targetable proteins, the KMT2 protein family showed consistently high variability between patient and corresponding xenografts. Comprehensive N terminomics revealed deregulated proteolytic processing in leukemic cells, in particular from caspase-driven cleavages found in patient cells. CONCLUSION: Genomic and host factors shape protein and post-translational modification landscapes differently. This study highlights select areas of diverging biology while confirming murinepatient-derived xenografts as a generally accurate model system.
Entities:
Keywords:
Leukemia; N termini; Phosphorylation; Proteolysis; Proteome; Xenograft
Authors: Charles G Mullighan; Letha A Phillips; Xiaoping Su; Jing Ma; Christopher B Miller; Sheila A Shurtleff; James R Downing Journal: Science Date: 2008-11-28 Impact factor: 47.728
Authors: Sarina Sulong; Anthony V Moorman; Julie A E Irving; Jonathan C Strefford; Zoe J Konn; Marian C Case; Lynne Minto; Kerry E Barber; Helen Parker; Sarah L Wright; Adam R M Stewart; Simon Bailey; Nick P Bown; Andrew G Hall; Christine J Harrison Journal: Blood Date: 2008-10-06 Impact factor: 22.113
Authors: Natalie C Marshall; Theo Klein; Maichael Thejoe; Niklas von Krosigk; Jayachandran Kizhakkedathu; B Brett Finlay; Christopher M Overall Journal: J Proteome Res Date: 2018-10-29 Impact factor: 4.466
Authors: Nikolaus Fortelny; Sharon Yang; Paul Pavlidis; Philipp F Lange; Christopher M Overall Journal: Nucleic Acids Res Date: 2014-10-20 Impact factor: 16.971
Authors: Dorte B Bekker-Jensen; Oliver M Bernhardt; Alexander Hogrebe; Ana Martinez-Val; Lynn Verbeke; Tejas Gandhi; Christian D Kelstrup; Lukas Reiter; Jesper V Olsen Journal: Nat Commun Date: 2020-02-07 Impact factor: 14.919
Authors: K Wang; M Sanchez-Martin; X Wang; K M Knapp; R Koche; L Vu; M K Nahas; J He; M Hadler; E M Stein; M S Tallman; A L Donahue; G M Frampton; D Lipson; S Roels; P J Stephens; E M Sanford; T Brennan; G A Otto; R Yelensky; V A Miller; M G Kharas; R L Levine; A Ferrando; S A Armstrong; A V Krivtsov Journal: Leukemia Date: 2016-06-13 Impact factor: 11.528
Authors: Zhengcheng He; Ryan Ghorayeb; Susanna Tan; Ke Chen; Amanda C Lorentzian; Jack Bottyan; Syed Mohammed Musheer Aalam; Miguel Angel Pujana; Philipp F Lange; Nagarajan Kannan; Connie J Eaves; Christopher A Maxwell Journal: Nat Commun Date: 2022-04-22 Impact factor: 17.694
Authors: Nina Rolf; Lorraine Y T Liu; Angela Tsang; Philipp F Lange; Chinten James Lim; Christopher A Maxwell; Suzanne M Vercauteren; Gregor S D Reid Journal: Cytometry A Date: 2021-06-25 Impact factor: 4.714